StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced that its former subsidiary, AccuStem Sciences, published new data demonstrating that StemPrintER is a strong prognostic tool for distant recurrence risk in breast cancer. Analyzing 776 tumor samples from the TransATAC cohort showed that patients with a low StemPrintER Risk Score had a 5.8% risk of distant recurrence at 10 years, compared to 23.2% for high scores. This indicates StemPrintER's potential in clinical decision-making, alongside established tests.
- StemPrintER shows strong prognostic ability for distant recurrence in breast cancer.
- Study demonstrated significantly lower risk of recurrence for low StemPrintER Risk Score patients (5.8% at 10 years).
- Research conducted on a substantial sample size (776 tumor samples) enhances credibility.
- None.
NEW YORK, March 01, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.’s (Nasdaq: TLSA) former subsidiary, AccuStem Sciences, Inc. (OTC PINK: ACMSY) (formerly AccuStem Sciences Ltd.), today announced publication of new data in the European Journal of Cancer. Results demonstrate that StemPrintER is highly prognostic for risk of distant recurrence in women with breast cancer.
Investigators from the European Institute of Oncology (IEO) in Milan and The Royal Marsden Hospital in London evaluated 776 tumor samples from the TransATAC cohort, a subgroup of estrogen receptor positive (ER+), post-menopausal patients from the prospective, randomized ATAC trial. The pivotal TransATAC study has been used to evaluate many of the commonly used breast cancer risk scoring assays, including OncotypeDX, Prosigna, EndoPredict and Breast Cancer Index.
In this analysis, investigators demonstrated that patients with a StemPrintER Risk Score (SPRS) Low result had significantly better outcomes than patients with a SPRS High result. Patients with a SPRS Low result had a
“Many genomic classifiers have been evaluated in the TransATAC cohort,” said Salvatore Pece, Full Professor at the Milan University Medical School and Director of the Hormone-Related Cancers and Stem Cell Pathobiology Lab at IEO. “It is exciting that StemPrintER appears to perform as well as other commercially-available tests and indicates the potential for this novel test to inform clinical decision making.”
Forward-Looking Statements
This press release contains “forward-looking statements” Forward-looking statements reflect our current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.
Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Tiziana Life Sciences Ltd. assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Media Contact:
| Tiziana Life Sciences Ltd Hana Malik, Business Development, and Investor Relations Manager +44 (0) 207 495 2379 email: info@tizianalifesciences.com | |
| Investors: Irina Koffler LifeSci Advisors, LLC 646.970.4681 ikoffler@lifesciadvisors.com |
- Pece, S., Sestak, I., Montani, F., Tillhon, M., Maisonneuve, P., Freddi, S., Chu, K., Colleoni, M., Veronesi, P., Disalvatore, D., Viale, G., Buus, R., Cuzick, J., Dowsett, M., & Di Fiore, P. P. (2022). Comparison of stemprinter with Oncotype DX recurrence score for predicting risk of breast cancer distant recurrence after endocrine therapy. European Journal of Cancer, 164, 52–61. https://doi.org/10.1016/j.ejca.2022.01.003
FAQ
What were the findings of the recent study published by Tiziana Life Sciences related to TLSA?
How does StemPrintER compare to other breast cancer risk scoring assays?
What is the significance of the TransATAC cohort in the TLSA study?
What is the risk of distant recurrence for patients with high StemPrintER Risk Scores?
